Cancer Conversations™ in MCL: Evolving Treatment Paradigms and Ongoing Trials

Get the latest evidence-based recommendations on treatment of mantle cell lymphoma with commentaries, downloadable slides, and an on-demand webcast capturing dynamic expert discussion on current challenges and controversies. Then, use the updated Interactive Decision Support Tool to view management recommendations for your patients from 5 renowned experts.

To Register: On the Event Dates page click a date/time, click blue Register button in upper right-hand corner. Once registered, you will receive a reminder email with a link to join in advance of the webinar.


Welcome and Introduction

Selecting Frontline Therapy for MCL
A discussion of therapy selection for patients with MCL in the frontline setting including evaluating transplant eligibility, therapies for patients with TP53 mutations, and ongoing clinical trials

Application of Novel Therapy in Relapsed/Refractory MCL
An examination of therapeutic strategies for relapsed/refractory MCL including BTK inhibitor selection, managing toxicities, BTK inhibitors in combination with other agents, the role of CAR T-cell therapy, and key ongoing clinical trials

Final Thoughts


Date / Time
Event Details


Program Director
Julie M. Vose, MD, MBA

Chief, Division of Oncology and Hematology
Neumann M. and Mildred E. Harris Professor
Department of Internal Medicine
University of Nebraska Medical Center
Omaha, Nebraska

Christopher R. Flowers, MD, MS

Department Chair
Department of Lymphoma/Myeloma
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas

John P. Leonard, MD

Richard T. Silver Distinguished Professor of Hematology and Medical Oncology
Professor of Medicine
Weill Cornell Medicine
New York Presbyterian Hospital
New York, New York

Goal Statement
The goal of this activity is to educate hematologists, oncologists, and other healthcare professionals in hematology/oncology about the recent developments in the care of MCL and incorporating new data and new therapies into their patient treatment plans.

Target Audience
This educational program is intended for hematologists, oncologists, and other healthcare professionals in hematology/oncology who care for patients with MCL.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Plan therapeutic strategies for patients with MCL based on diagnostic classification, patient age and fitness, and risk stratification
  • Integrate the available clinical data, treatment guidelines, and expert recommendations when selecting treatment of newly diagnosed and R/R MCL
  • Recognize and manage adverse events associated with current and recently approved systemic therapies in MCL
  • Evaluate the available clinical data on promising investigational agents and treatment approaches for appropriate patients with MCL including clinal trial enrollment


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation 

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.